Tarek Mouhieddine, MD
@tarekmd91
Followers
2K
Following
8K
Media
33
Statuses
1K
@AUB_Lebanon | @DanaFarber | @IcahnMountSinai | @SinaiHemeOnc Fellow @TischCancer | Physician-scientist #multiplemyeloma #myeloma #mmsm 🇱🇧🇺🇸
New York, NY
Joined October 2011
RT @VincentRK: Just out! New IMS/ IMWG Definition of High Risk Myeloma. @JCO_ASCO #IMWG25. @Myeloma_Society @IMFmyeloma @NikhilMunshiMD @m….
0
117
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Biallelic antigen escape may be mechanism of resistance to anti-CD38 antibodies; L153H & C275Y….
0
9
0
RT @FrancescoMaura4: Happy to share our new work out today on @BloodPortfolio #Blood where we report CD38 loss as recurrent mechanisms of r….
0
18
0
RT @TischCancer: @HJChoMDPhD1 discusses advancements in treating #MultipleMyeloma .@IcahnMountSinai @theMMRF.
people.com
At 38, author Jonathan Gluck was diagnosed with blood cancer and given less than three years to live. Twenty-two years later, he has written a memoir about living with the incurable disease.
0
6
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: MIDAS study of MRD-guided consolidation strategy in pts eligible for ASCT finds those who were….
0
11
0
Outstanding cilta-cel results and even more amazing is that I get to see some of those myeloma patients who are potentially “cured” in clinic at Mount Sinai! #mmsm @TischCancer.
The most impressive myeloma abstract at #ASCO25 . Outstanding longterm efficacy with cilta-cel CAR-T. 5 year survival rate 50%.5 year PFS rate of 33%. Astounding given multi-drug relapsed refractory setting. @PlasmaCellPete @NoopurRajeMD @TomBmt133 @YiLinMDPhD @DMadduri.
0
0
10
RT @JbAlberge: 1/ 🧵Check out our new study in @NatureGenet, which examines how precancerous conditions (MGUS/SMM) evolve into Multiple Myel….
0
26
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Multiomic analysis of #Waldenström macroglobulinemia finds two disease subtypes, including memo….
0
10
0
RT @TischCancer: Extramedullary disease but not paraskeletal disease portends inferior outcomes after CAR T cell therapy in #MultipleMyelom….
0
6
0
RT @TischCancer: Practice-Changing Studies in Multiple Myeloma With Samir Parekh, MBBS .#MultipleMyeloma @IcahnMoun….
0
4
0
Thank you @oncodaily for taking an interest in my journey and sharing my story.
🎙️ Cancer Through My Eyes – Ep. 11. When a myeloma patient had no options left, Dr. Tarek Mouhieddine (@tarekmd91) helped secure a newly approved immunotherapy — within 24 hours of FDA approval. 💥 That moment changed everything. Now at Mount Sinai, his research in T cell–based
1
4
24
RT @Myeloma_Doc: #Myeloma Paper of the Day: Impact of clonal hematopoiesis on clinical outcomes to BCMA CAR-T in myeloma includes higher ri….
0
15
0
RT @TischCancer: Samir Parekh is named Director of Center of Excellence for Multiple Myeloma.@IcahnMountSinai #mult….
0
6
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Flatiron health record analysis comparing carfilzomib dosing in relapsed/refractory myeloma fin….
0
9
0
RT @AuclairDan: Beautiful work presented at @Myeloma_Society workshop by Dr. @Samir Parekh @IcahnMountSinai on the involvement of S10….
0
3
0
RT @Myeloma_Doc: #Myeloma Paper of the Day: Clonal hematopoiesis frequently co-exists w/ myeloma @ dx, associates w/ more advanced stage, a….
0
13
0
RT @JoshuaRichterMD: Are you joining us tomorrow for iwGPRC5d? @RossFirestone @TomasJelinekMD @andrew02114 @RahulBanerjeeMD #….
0
8
0
RT @RomanosSP: Our paper on establishing targeted therapy for MM with 1q+ is online ahead of print in @BloodJournal! w/ Liz Lightbody, Mair….
0
14
0
RT @RahulBanerjeeMD: 1/ The "this shoulda been an oral" #MMsm poster of #Tandem25 - worth reviewing if you use cilta-cel!. Rapid or sustain….
0
19
0
CD4+ T-Cell Lymphoma Harboring a Chimeric Antigen Receptor Integration in TP53 | New England Journal of Medicine
www.nejm.org
Malignant T-cell transformation after chimeric antigen receptor (CAR) T-cell therapy has been described, but the contribution of CAR integration to oncogenesis is not clear. Here we report a case o...
0
0
7